Mixed data for Renovo's scarring therapy

Renovo's Juvista produced a mixed set of data in two mid-stage trials. The drug produced positive data in reducing scarring but failed to demonstrate efficacy during a breast augmentation trial. Researchers also said that the therapy was more effective against scarring when administered twice and noted that during the breast augmentation trial the drug was administered once. Renovo plans to launch a Phase III trial of Juvista in the second half of this year. Shire, a partner on the drug, agreed to invest $75 million in Juvista, plus make a $50 million equity investment in Renovo.

"Shire is at present assessing these latest results with all other results produced to date and plans to discuss these with the FDA in 2008 to determine the regulatory path forward in the United States," said Renovo in a statement.

- read the press release for more information

Related Articles:
Renovo inks $875M deal for scarring drug. Report
Renovo CEO bullish on partnership prospects. Report
Renovo sees shares jump on first day. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.